Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2023-302108853.html
https://www.prnewswire.com/news-releases/galmed-announces-grant-of-new-patent-for-the-combination-of-aramchol-with-resmetirom-mgl-3196-rezdiffra-for-the-treatment-of-nash-and-liver-fibrosis-302090340.html
https://www.prnewswire.com/news-releases/galmed-announces-a-delay-in-the-initiation-of-its-primary-sclerosing-cholangitis-psc-phase-2a-study-301994036.html
https://www.prnewswire.com/news-releases/galmed-announces-allowance-of-new-patent-for-aramchol-for-the-treatment-of-pulmonary-and-dermal-fibrosis-301938861.html
https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-announces-receipt-of-nasdaq-minimum-bid-price-notification-301934926.html
https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-announces-pricing-of-7-million-public-offering-301877539.html
https://www.prnewswire.com/news-releases/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-trial-in-psc-301872804.html
https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-reports-first-quarter-2023-financial-results-and-recent-developments-301839999.html
https://www.prnewswire.com/news-releases/galmed-announces-initiation-of-a-clinical-development-program-to-evaluate-aramchol-meglumine-for-the-treatment-of-primary-sclerosing-cholangitis-psc-301819268.html
https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-forms-a-strategic-partnership-with-onkai-301816388.html